์ํผ์ค๋ฆฐ/์ค๋ฐํ
**์ํผ์ค๋ฆฐ/์ค๋ฐํ(Ampicillin/sulbactam)**์ ์ฃผ์ฌ์ฉ ๊ฐํ ์๋ฏธ๋ ธํ๋์ค๋ฆฐ์ ๋๋ค. ์ํผ์ค๋ฆฐ์ ๊ด๋ฒ์ ์ด๊ท ํ์ฑ๊ณผ ๋ฒ ํ๋ฝํ๋ง์ ์ต์ ์ ์ธ ์ค๋ฐํ์ด ๊ฒฐํฉ๋์ด ์์ต๋๋ค. * **ํญ๊ท ์คํํธ๋ผ**: ๋ฒ ํ๋ฝํ๋ง์ ๋ฅผ ์์ฑํ๋ ๋์ฅ๊ท , ํ์คํด๋ ๋ผ, ํฌ๋์๊ตฌ๊ท , ํด๋ ๋ธ์์๋ผ, ํ๋กํ ์ฐ์ค์ ์ฌ๋ฌ ๊ท ์ฃผ์ ํจ๊ณผ์ ์ ๋๋ค. ํด๋ก์คํธ๋ฆฌ๋์ ๋ฐ ๋ฐํ ๋ก์ด๋ฐ์ค์ ๊ฐ์ ํ๊ธฐ์ฑ ์ธ๊ท ์๋ ํจ๊ณผ๊ฐ ์์ต๋๋ค. * **์์์ ์ ์ฉ์ฑ**: ์ฃผ๋ก ๊ฐ์ ๊ณ ์์ด์์ ๊ฒฝ๊ตฌ์ฉ ์๋ชฉ์์ค๋ฆฐ/ํด๋ผ๋ถ๋์ฐ ํฌ์ฌ๊ฐ ๋ถ๊ฐ๋ฅํ๊ฑฐ๋(์: ๊ธ์, ์ค์ฆ ํ์, ๊ตฌํ ), ํจํ์ฆ, ํ๋ ด, ์ฌ๊ฐํ ๊ต์ ๋ฑ ์ค์ฆ ๊ฐ์ผ์ผ๋ก ์ธํด ๊ณ ๋๋์ ์ฃผ์ฌ ํฌ์ฌ๊ฐ ํ์ํ ๋ ์ฌ์ฉ๋ฉ๋๋ค. * **ํ๊ณ**: ๋ น๋๊ท ๋ฐ ํน์ ์ 1ํ ๋ฒ ํ๋ฝํ๋ง์ ์์ฑ๊ท (์ํ ๋ก๋ฐํฐ, ์ธ๋ผํฐ์ ๋ฑ)์๋ ํจ๊ณผ๊ฐ ์์ต๋๋ค. > **์์ ์์ **: ๋์ผ ์ฉ๋ ๊ธฐ์ค์ผ๋ก ํด๋ผ๋ถ๋์ฐ์ด ์ค๋ฐํ๋ณด๋ค ๋ ๊ฐ๋ ฅํ ๋ฒ ํ๋ฝํ๋ง์ ์ต์ ์ ์ด์ง๋ง, ์ค๋ฐํ์ ์ผ์์ฒด์ฑ ๋ฒ ํ๋ฝํ๋ง์ ์ ๋ฐ ๊ฐ๋ฅ์ฑ์ด ์ ๊ณ ์กฐ์ง ์นจํฌ๋ ฅ๊ณผ ์์ ์ฑ์ด ๋ ๋ฐ์ด๋๋ค๋ ์ฅ์ ์ด ์์ต๋๋ค.
์์ฉ ๊ธฐ์ : * **Ampicillin** binds to **penicillin-binding proteins (PBPs)** located inside the bacterial cell wall โ inhibits the third and final stage of bacterial cell wall synthesis โ cell lysis and death. * **Sulbactam** irreversibly binds to and inactivates **beta-lactamases** (Richmond-Sykes types II-VI) โ protects the **beta-lactam ring** of ampicillin from enzymatic hydrolysis. * *Note*: Sulbactam has weak intrinsic antibacterial activity against certain organisms (*Neisseria*, *Moraxella*, *Bacteroides*) by binding to specific PBPs, providing a synergistic effect when combined with ampicillin.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- For respiratory infections using ampicillin/sulbactam (Unasynยฎ) ยท 50 mg/kg (combined) IV q8h ยท IV ยท q8h
- As adjunctive treatment of serious bite wounds ยท 30-50 mg/kg q8h IV ยท IV ยท q8h
- For intra-abdominal infections ยท 20 mg/kg IV or IM q6-8h ยท IV/IM ยท q6-8h ยท Extrapolation of human dose with limited studies in dogs and cats
- For respiratory infections ยท 50 mg/kg (combined) IV q8h ยท IV ยท q8h
- For respiratory infections ยท 20 mg/kg IV or IM q6-8h ยท IV/IM ยท q6-8h
- As adjunctive treatment of serious bite wounds ยท 30-50 mg/kg q8h IV ยท IV ยท q8h
- For intra-abdominal infections ยท 20 mg/kg IV or IM q6-8h ยท IV/IM ยท q6-8h ยท Extrapolation of human dose with limited studies in dogs and cats
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Patients with a history of severe hypersensitivity (e.g., anaphylaxis) to penicillins
์ด์๋ฐ์
- Pain at intramuscular injection sites
- Thrombophlebitis (with intravenous injection)
- Hypersensitivity reactions (including severe anaphylaxis, particularly after IV administration)
- Neurotoxicity (e.g., ataxia in dogs) at high doses or prolonged use
- Elevated liver enzymes
- Tachypnea, dyspnea, edema, and tachycardia (reported in dogs)
์ฝ๋ฌผ ์ํธ์์ฉ
- Aminoglycosides (amikacin, gentamicin, tobramycin) ยท In vitro inactivation if mixed together; synergistic in vivo, but penicillins can inactivate aminoglycosides in patients with renal failure or when used in massive dosages. Amikacin is the most resistant to this inactivation.
- Bacteriostatic antimicrobials (chloramphenicol, macrolides, tetracyclines, sulfonamides) ยท Potential in vitro antagonism between beta-lactam antibiotics and bacteriostatic antibiotics; clinical importance is unclear.
- Probenecid ยท Reduces the renal tubular secretion of both ampicillin and sulbactam, maintaining higher systemic levels for a longer period.
๋ชจ๋ํฐ๋ง
- Clinical efficacy (resolution of infection signs)
- Adverse effects (signs of hypersensitivity, neurological symptoms at high doses)
๊ณผ์ฉ๋
Neurological effects (e.g., ataxia) have rarely been reported in dogs receiving very high dosages of penicillins. In humans, very high dosages of parenteral penicillins, especially in those with renal disease, have induced CNS effects. If neurological signs develop, weigh the risks of continued use versus dosage reduction or switching to a different antibiotic class.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.